Form 4: MaxCyte CEO Maher Masoud Increases Stake in Company with Recent Stock Purchases
SEC Form 4 Filing
MaxCyte's President and CEO, Maher Masoud, recently acquired a significant number of company shares through multiple transactions.
Summary
- Maher Masoud, President and CEO of MaxCyte, Inc., has reported changes in beneficial ownership of the company's stock.
- On June 7, 2024, Masoud acquired 29,557 shares of common stock at a weighted average price of $4.866 per share.
- These shares were purchased in multiple transactions with prices ranging from $4.84 to $4.95.
- On June 10, 2024, he acquired an additional 70,443 shares at a weighted average price of $4.901 per share.
- These shares were purchased in multiple transactions with prices ranging from $4.77 to $5.00.
- Following these transactions, Masoud directly owns 100,000 shares of MaxCyte common stock.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the CEO's increased investment in the company, which can be interpreted as a sign of confidence. However, it's a routine filing, so the impact is limited.
Positives
- The CEO's increased investment in the company may signal confidence in MaxCyte's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- Shareholders may view the CEO's stock purchases as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Maher Masoud purchased 29,557 shares of MaxCyte common stock. |
| 06/10/2024 | Maher Masoud purchased 70,443 shares of MaxCyte common stock. |
| 06/10/2024 | Filing date of the SEC Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.